Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $144,319.91 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 707 shares of Natera stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $204.13, for a total transaction of $144,319.91. Following the completion of the transaction, the insider owned 189,199 shares in the company, valued at $38,621,191.87. This trade represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

John Fesko also recently made the following trade(s):

• On Tuesday, February 3rd, John Fesko sold 3,594 shares of Natera stock. The shares were sold at an average price of $231.02, for a total transaction of $830,285.88.
• On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $220,548.48.
• On Tuesday, January 27th, John Fesko sold 784 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $188,575.52.
• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The stock was sold at an average price of $235.00, for a total value of $79,665.00.
• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $4,179,780.44.

Natera Stock Down 1.3%

Shares of NASDAQ:NTRA opened at $187.85 on Friday. The company has a market cap of $26.62 billion, a price-to-earnings ratio of -122.78 and a beta of 1.65. The business has a 50 day moving average price of $219.73 and a 200 day moving average price of $206.14. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same period in the previous year, the business posted ($0.41) EPS. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently made changes to their positions in the business. Reflection Asset Management bought a new stake in Natera in the fourth quarter valued at about $29,000. Palladiem LLC acquired a new position in Natera in the fourth quarter worth about $31,000. Horizon Investments LLC bought a new position in Natera during the third quarter worth about $32,000. Bank of Jackson Hole Trust boosted its holdings in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 110 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research reports. Citigroup initiated coverage on shares of Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price on the stock. Barclays raised their price target on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. Robert W. Baird upped their price objective on shares of Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.